New top operating officer, President William Edwards, joined the drug chain at an initial annual salary of $425,000, according to proxy materials prepared for Revco's Sept. 27 annual meeting. Edwards was previously the president of a deep-discounting drug chain in Detroit, F&M Distributors.
You may also be interested in...
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
The US agency has announced another month of webinars aimed at labs and manufacturers that are (or have) developed diagnostic tests for the novel coronavirus.
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.